Mycolactone diffuses into the peripheral blood of buruli ulcer patients - implications for diagnosis and disease monitoring

PLoS Neglected Tropical Diseases

Volumn 5, Issue 7, 2011, Pages

  Sarfo, Fred S ^a   Chevalier, Fabien ^b   Aka, N'Guetta ^c   Phillips, Richard O ^a,d   Amoako, Yaw ^a   Boneca, Ivo G ^b,e   Lenormand, Pascal ^b   Dosso, Mireille ^c   Wansbrough Jones, Mark ^f   Veyron Churlet, Romain ^b   Guenin Macé, Laure ^b   Demangel, Caroline ^b  

^a KOMFO ANOKYE TEACHING HOSPITAL   (Ghana)

^b INSTITUT PASTEUR   (France)

^c INSTITUT PASTEUR DE CÔTE D'IVOIRE   (Côte d’Ivoire)

^d KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^e INSERM   (France)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; MYCOLACTONE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BIOLOGICAL MARKER;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; BURULI ULCER; CONTROLLED STUDY; FEMALE; FLUORESCENCE ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; MASS SPECTROMETRY; PATIENT MONITORING; POINT OF CARE TESTING; PROGNOSIS; THIN LAYER CHROMATOGRAPHY; BLOOD; CHEMISTRY; EXUDATE; INJURY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MONONUCLEAR CELL; MYCOBACTERIUM ULCERANS;

ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BACTERIAL TOXINS; BIOLOGICAL MARKERS; BURULI ULCER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, THIN LAYER; EXUDATES AND TRANSUDATES; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MASS SPECTROMETRY; MYCOBACTERIUM ULCERANS; WOUNDS AND INJURIES;

EID: 79960956034     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001237     Document Type: Article

References (26)

1. Silva MT, Portaels F, Pedrosa J, (2009) Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis 9: 699-710.
2. Walsh DS, Portaels F, Meyers WM, (2010) Recent advances in leprosy and Buruli ulcer (Mycobacterium ulcerans infection). Curr Opin Infect Dis 23: 445-455.
3. Etuaful S, Carbonnelle B, Grosset J, Lucas S, Horsfield C, et al. (2005) Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 49: 3182-3186.
4. Chauty A, Ardant MF, Adeye A, Euverte H, Guedenon A, et al. (2007) Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother 51: 4029-4035.
5. Johnson PD, (2010) Should antibiotics be given for Buruli ulcer? Lancet 375: 618-619.
6. Sarfo FS, Phillips R, Asiedu K, Ampadu E, Bobi N, et al. (2010) Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother 54: 3678-3685.
7. Nienhuis WA, Stienstra Y, Thompson WA, Awuah PC, Abass KM, et al. (2010) Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375: 664-672.
8. George KM, Chatterjee D, Gunawardana G, Welty D, Hayman J, et al. (1999) Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283: 854-857.
9. Hong H, Demangel C, Pidot SJ, Leadlay PF, Stinear T, (2008) Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria. Nat Prod Rep 25: 447-454.
10. Demangel C, Stinear TP, Cole ST, (2009) Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol 7: 50-60.
11. Sarfo FS, Phillips RO, Rangers B, Mahrous EA, Lee RE, et al. (2010) Detection of Mycolactone A/B in Mycobacterium ulcerans-infected human tissue. PLoS Negl Trop Dis 4: e577.
12. Hong H, Coutanceau E, Leclerc M, Caleechurn L, Leadlay PF, et al. (2008) Mycolactone diffuses from Mycobacterium ulcerans-infected tissues and targets mononuclear cells in peripheral blood and lymphoid organs. PLoS Negl Trop Dis 2: e325.
13. Spangenberg T, Kishi Y, (2010) Highly sensitive, operationally simple, cost/time effective detection of the mycolactones from the human pathogen Mycobacterium ulcerans. Chem Commun 46: 1410-1412.
14. Hong H, Stinear T, Skelton P, Spencer JB, Leadlay PF, (2005) Structure elucidation of a novel family of mycolactone toxins from the frog pathogen Mycobacterium sp. MU128FXT by mass spectrometry. Chem Commun 14: 4306-4308.
15. Phillips R, Sarfo FS, Guenin-Mace L, Decalf J, Wansbrough-Jones M, et al. (2009) Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with Buruli ulcer disease. J Infect Dis 200: 1675-84.
16. Sarfo FS, Phillips RO, Ampadu E, Sarpong F, Adentwe E, et al. (2009) Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol 16: 61-65.
17. Yeboah-Manu D, Peduzzi E, Mensah-Quainoo E, Asante-Poku A, Ofori-Adjei D, et al. (2006) Systemic suppression of interferon-gamma responses in Buruli ulcer patients resolves after surgical excision of the lesions caused by the extracellular pathogen Mycobacterium ulcerans. J Leukoc Biol 79: 1150-1156.
18. Beissner M, Herbinger KH, Bretzel G, (2010) Laboratory diagnosis of Buruli ulcer disease. Future Microbiol 5: 363-370.
19. Callaway TR, Anderson RC, Edrington TS, Jung YS, Bischoff KM, et al. (2004) Effects of sodium chlorate on toxin production by Escherichia coli O157:H7. Curr Issues Intest Microbiol 5: 19-22.
20. Gordon CL, Buntine JA, Hayman JA, Lavender CJ, Fyfe JA, et al. (2010) All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis 4: e770.
21. Pahlevan AA, Wright DJ, Andrews C, George KM, Small PL, et al. (1999) The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol 163: 3928-3935.
22. Boulkroun S, Guenin-Mace L, Thoulouze MI, Monot M, Merckx A, et al. (2010) Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol 184: 1436-1444.
23. Coutanceau E, Decalf J, Martino A, Babon A, Winter N, et al. (2007) Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone. J Exp Med 204: 1395-1403.
24. Coutanceau E, Marsollier L, Brosch R, Perret E, Goossens P, et al. (2005) Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin. Cell Microbiol 7: 1187-1196.
25. Simmonds RE, Lali FV, Smallie T, Small PL, Foxwell BM, (2009) Mycolactone inhibits monocyte cytokine production by a posttranscriptional mechanism. J Immunol 182: 2194-2202.
26. Schutte D, Pluschke G, (2009) Immunosuppression and treatment-associated inflammatory response in patients with Mycobacterium ulcerans infection (Buruli ulcer). Expert Opin Biol Ther 9: 187-200.